Stephen M. Ansell - Böcker

Many comprehensive text books have been written about the common hematologic malignancies. However, every practicing hematologist/oncologist or primary care physician intermittently encounters patients with uncommon or rare hematologic malignancies. Information concerning these diseases, and particularly regarding their management, is extremely difficult to find. Physicians will commonly spend a substantial period of time searching the medical literature for help or will call a colleague who may have greater expertise in the area.Rare Hematological Malignancies covers malignant hematologic diseases that physicians would see only occasionally, providing accurate, up-to-date information on the disease biology and practical recommendations concerning the disease management.

Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies A thorough compilation of the many scientific breakthroughs in the ongoing development of precision cancer therapies related to lymphoma Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice focuses on lymphoma, an area which has seen a remarkable number of breakthroughs in the ongoing development of precision cancer therapies. Each section on a specific biology or class of drugs has an introductory chapter written by an authority in the field, exclusively focused on the science and its relevance to cancer biology. This approach addresses the need for scientists, physicians, and the private sector to understand the broader context of the extraordinary advances that have produced such astonishing advances in the disease. The work primarily focuses on how to understand and translate fundamental principles of basic science into information that can be directly applied to patients – hence the subtitle, From Concept to Practice. To aid in readers’ comprehension, the first page of each chapter contains a box entitled ‘Take Home Points’. This short text will highlight the major unique points about the information contained within the chapter. Some of the key topics addressed in the work are as follows: Biological basis of the lymphoid malignancies: fundamental principles of lymphomagenesis and molecular classification of lymphoid malignanciesTargeting programmed cell death: principles for understanding the many types of cell death and promising combinations of drugs targeting apoptosisTargeting the PI3K pathway: understanding the intricacies of this complex biology and precisely how targeted drugs can be leveraged therapeuticallyTargeting the cancer epigenome: pharmacologic features of drugs targeting the epigenome and future prospects for targeting various aspects of epigenetic controlTargeting the tumour proteome: understanding the mechanisms of protein degradation in cancer including both older drugs like proteasome inhibitors, and newer PROTAC based approachesWritten primarily for scientists and physicians in both the public and private sectors, Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice is a comprehensive reference work for those interested in the growing area of Precision Cancer Therapies. Seamlessly integrating the basic and applied science, this volume will be an indispensable reference for those interested in translating the most important advances in science to innovative novel treatments for patients.

Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science. Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T). Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also: Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biologyFocuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanismsCovers FDA-approved drugs and their indications, as well as drugs currently in developmentProvides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacyIncludes boxed sections highlighting major unique points about the information in the chapter Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject.